BioCentury
ARTICLE | Top Story

ALLP suspends Phase III cardiac study

January 9, 2001 8:00 AM UTC

Alliance Pharmaceutical (ALLP) said it voluntarily suspended enrollment in a Phase III study of its Oxygent perflubron blood substitute in combination with hemodilution in 600 cardiac surgery patients...